A novel p21 attenuator which is structurally related to sorafenib

Cancer Biology and Therapy

Volumn 14, Issue 3, 2013, Pages 278-285

  Wettersten, Hiromi I ^a,b   Hwang, Sung Hee ^b,c   Li, Cuiwen ^a   Shiu, Eunice Y ^a   Wecksler, Aaron T ^b,c   Hammock, Bruce D ^b,c   Weiss, Robert H ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; P21; P21 inhibitor; Proliferation; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOHEXIMIDE; MESSENGER RNA; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; RAF PROTEIN; SORAFENIB; UC2288; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; KIDNEY CANCER; KIDNEY PROXIMAL TUBULE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY;

APOPTOSIS; P21; P21 INHIBITOR; PROLIFERATION; SORAFENIB;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RAF KINASES; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874887926     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23374     Document Type: Article

References (30)

1. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003; 4:425-9; PMID:14706334; http://dx.doi.org/10.1016/ S1535-6108(03)00308-8. (Pubitemid 38050039)
2. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci U S A 2000; 97:12782-7; PMID:11070090; http://dx.doi. org/10.1073/pnas.97.23.12782.
3. Griffin SV, Shankland SJ. Not just an inhibitor: a role for p21 beyond the cell cycle-"The truth is rarely pure and never simple". J Am Soc Nephrol 2004; 15:825-6; PMID:14978186; http://dx.doi.org/10.1097/01. ASN.0000117896.79378.43. (Pubitemid 38294814)
4. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011; 121:1549-60; PMID:21403397; http://dx.doi. org/10.1172/JCI44539.
5. Bedelbaeva K, Snyder A, Gourevitch D, Clark L, Zhang XM, Leferovich J, et al. Lack of p21 expression links cell cycle control and appendage regeneration in mice. Proc Natl Acad Sci U S A 2010; 107:5845-50; PMID:20231440; http://dx.doi.org/10.1073/pnas.1000830107.
6. Weiss RH, Joo A, Randour C. p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 2000; 275:10285-90; PMID:10744715; http://dx.doi.org/10.1074/jbc.275.14.10285. (Pubitemid 30202086)
7. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400-14; PMID:19440234; http://dx.doi.org/10. 1038/nrc2657.
8. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25; PMID:8242752; http://dx.doi.org/10.1016/0092-8674(93)90500-P. (Pubitemid 23346378)
9. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999; 18:1223-34; PMID:10064589; http://dx.doi.org/10. 1093/emboj/18.5.1223. (Pubitemid 29110307)
10. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 2003; 5:R242-9; PMID:14580260; http://dx.doi. org/10.1186/bcr654.
11. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, et al. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 2007; 177:63-8, discussion 68-9; PMID:17162001; http://dx.doi. org/10.1016/j.juro.2006.08.073.
12. Zhang, W. et al. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1995;1:1051-7.
13. Ferrandina G, Stoler A, Fagotti A, Fanfani F, Sacco R, De Pasqua A, et al. p21WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol 2000; 17:1231-5; PMID:11078810.
14. Baretton GB, Klenk U, Diebold J, Schmeller N, Löhrs U. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 1999; 80:546-55; PMID:10408865; http://dx.doi. org/10.1038/sj.bjc.6690390. (Pubitemid 29213212)
15. Park SH, Park JY, Weiss RH. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J Urol 2008; 180:352-60; PMID:18499163; http://dx.doi. org/10.1016/j.juro.2008.02.038.
16. Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol 2012; 2012:170325; PMID:22911014; http://dx.doi.org/10.1155/2012/170325.
17. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011; 6:1130-46; PMID:21744502; http://dx.doi.org/10.1002/biot.201100054.
18. Park SH, Wang X, Liu R, Lam KS, Weiss RH. High throughput screening of a small molecule onebead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol Ther 2008; 7:2015-22; PMID:18981726; http://dx.doi.org/10.4161/cbt.7.12.7069.
19. Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther 2011; 12:827-36; PMID:21878748; http://dx.doi. org/10.4161/cbt.12.9.17680.
20. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5:835-44; PMID:17016424; http://dx.doi.org/10. 1038/nrd2130. (Pubitemid 44480537)
21. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57:4285-300; PMID:9331090. (Pubitemid 27413438)
22. Li Y, Dowbenko D, Lasky LA. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002; 277:11352-61; PMID:11756412; http://dx.doi. org/10.1074/jbc. M109062200. (Pubitemid 34952901)
23. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Aktinduced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3:245-52; PMID:11231573; http://dx.doi.org/10.1038/35060032. (Pubitemid 32201319)
24. Dong Y, Chi SL, Borowsky AD, Fan Y, Weiss RH. Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal 2004; 16:263-9; PMID:14636896; http://dx.doi.org/10.1016/S0898-6568(03)00136-0. (Pubitemid 37431174)
25. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351:453-6; PMID:2046748; http://dx.doi.org/10.1038/351453a0. (Pubitemid 21896613)
26. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78; PMID:8069852. (Pubitemid 24289415)
27. Motzer, RJ, Bukowski, RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Onco 2006;24: 5601-8; http://dx.doi.org/10.1200/JCO.2006.08. 5415. (Pubitemid 46631341)
28. Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther 2009; 8:2193-203; PMID:19671760; http://dx.doi.org/10.1158/1535-7163.MCT-09-0119.
29. Fan Y, Borowsky AD, Weiss RH. An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther 2003; 2:773-82; PMID:12939467.
30. Jester BW, Cox KJ, Gaj A, Shomin CD, Porter JR, Ghosh I. A coiled-coil enabled split-luciferase threehybrid system: applied toward profiling inhibitors of protein kinases. J Am Chem Soc 2010; 132:11727-35; PMID:20669947; http://dx.doi.org/10.1021/ja104491h.